Want to see FBIO full AI Analyst Report?
Top Page
Fortress Biotech
(NASDAQ:FBIO)
Select Model
Select Model
Rating:55Neutral
Price Target:
$3.00
▼(-10.18% Downside)
Action:Reiterated
Date:07/15/26
The score is held back primarily by weak cash flow and ongoing operating losses (negative EBIT/EBITDA) despite improved revenue and gross margin. Offsetting this, the stock shows strong technical momentum with price above key moving averages, though overbought signals increase near-term pullback risk. Valuation appears inexpensive based on the very low P/E, but without dividend data and with cash burn, that support is less certain.
Positive Factors
Diversified portfolio model
Fortress’s holding-company structure provides durable diversification: multiple subsidiaries across indications spread clinical and commercial risk, while shared services and capital-markets access let the parent recycle capital and support assets through development, improving long-term resilience.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow shows the business still burns cash despite recent improvements. Over the medium term this creates dependence on external financing or asset monetization, constraining sustainable investment and increasing dilution/refinancing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified portfolio model
Fortress’s holding-company structure provides durable diversification: multiple subsidiaries across indications spread clinical and commercial risk, while shared services and capital-markets access let the parent recycle capital and support assets through development, improving long-term resilience.
Read all positive factors
Fortress Biotech (FBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$91.35M
Dividend YieldN/A
Average Volume (3M)569.80K
Price to Earnings (P/E)0.9
Beta (1Y)0.76
Revenue Growth14.50%
EPS GrowthN/A
CountryUS
Employees78
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.27
Shares Outstanding33,219,070
10 Day Avg. Volume642,773
30 Day Avg. Volume569,798
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)2.05
Price to Sales (P/S)1.61
P/FCF Ratio-1.55
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside49.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.4
Revenue Forecast (FY)$79.88M
Fortress Biotech Business Overview & Revenue Model
Company Description
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. ...
How the Company Makes Money
Fortress Biotech generates revenue primarily through its portfolio-company model. Key sources include: (1) Collaboration and licensing arrangements: Fortress and/or its subsidiaries may enter into license, collaboration, or commercialization agree...
Fortress Biotech Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call conveyed clear commercial momentum for Emrosi — strong revenue growth (+23% YoY total revenue), accelerating prescriptions (20% sequential growth to ~36k in Q2), rising prescriber counts (>4,500, >40% increase from end-2025), improving ASP and formulary progress, and a meaningful move to positive EBITDA and adjusted EBITDA. These positives outweigh the remaining challenges: payer friction (only ~38% high-quality coverage), some softness in QBREXZA, refill dynamics still maturing, and the time required to monetize international opportunities. Management signaled measured investment in marketing and added sales capacity to sustain growth. Overall, the trajectory appears constructive with manageable risks.Positive Updates
Total Revenue Growth
Total revenue for Q2 2026 was $18.5M, up 23% year-over-year from $15.0M in Q2 2025, driven primarily by Emrosi commercial momentum.
Negative Updates
Remaining Payer Friction and Limited High-Quality Coverage
Despite improvement to ~38% high-quality formulary coverage (single-step or better), roughly 62% of covered commercial lives still face greater access friction (prior authorizations, double-step edits). Management emphasized these barriers remain and require ongoing negotiations to remove.
Read all updates
Q2-2026 Updates
Positive
Negative
Total Revenue Growth
Total revenue for Q2 2026 was $18.5M, up 23% year-over-year from $15.0M in Q2 2025, driven primarily by Emrosi commercial momentum.
Read all positive updates
Company Guidance
Management reiterated that 2026 should be a "breakout year" for revenue growth and profitability, expecting continued ASP improvement and expanding payer coverage (quality formulary coverage rose from 34% in Q1 to ~38% currently, and GPO agreements give plan access to ~169M of 192M commercial lives); they reported Q2 total revenue of $18.5M (up 23% YoY from $15M) with Emrosi net revenue of $8.1M, gross margin of 67%, SG&A of $10.9M (down from $11.9M), GAAP net loss narrowed to $0.3M ($0.01/sh), positive EBITDA of $1.4M in Q2 ($1.1M for the six months) and adjusted EBITDA of $2.9M in Q2 ($3.5M YTD), ending the quarter with $25.6M cash, and said they expect to remain EBITDA‑positive for the remainder of the year and to become sustainably earnings‑ and cash‑flow‑positive; operationally they expect continued Emrosi prescription momentum (Q2 ~36,000 scripts vs ~30,000 in Q1, ~20% sequential growth; June ~13K and July ~14K monthly scripts; NRx ~5,300 in June vs a prior 3‑month average of ~4,700; >4,500 unique prescribers vs 3,200 at end‑2025, >40% growth), contributions from five new dermatology reps deployed in late July, and support from the late‑Q2 launch of Eurax cream to drive further ASP, revenue and payer traction through Q3/Q4 and into 2028.Fortress Biotech Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.59M | 63.26M | 57.67M | 84.51M | 75.74M | 68.79M |
| Gross Profit | 31.21M | 42.34M | 36.80M | 61.62M | 44.97M | 36.71M |
| EBITDA | 146.43M | -20.16M | -104.49M | -135.72M | -193.69M | -146.17M |
| Net Income | 109.81M | 6.82M | -46.00M | -60.64M | -86.58M | -64.70M |
Balance Sheet | ||||||
| Total Assets | 316.71M | 185.55M | 144.22M | 167.53M | 294.30M | 396.50M |
| Cash, Cash Equivalents and Short-Term Investments | 196.58M | 79.38M | 57.26M | 80.93M | 178.27M | 305.74M |
| Total Debt | 53.32M | 74.30M | 75.96M | 84.66M | 127.34M | 74.98M |
| Total Liabilities | 110.63M | 123.36M | 145.87M | 165.94M | 244.28M | 170.63M |
| Stockholders Equity | 164.14M | 49.87M | 22.74M | 22.54M | 41.72M | 108.67M |
Cash Flow | ||||||
| Free Cash Flow | 185.20M | -65.78M | -95.19M | -136.32M | -182.46M | -132.89M |
| Operating Cash Flow | 185.20M | -65.78M | -80.19M | -128.22M | -179.40M | -116.54M |
| Investing Cash Flow | 2.87M | 10.12M | -15.00M | -2.10M | -22.93M | 40.51M |
| Financing Cash Flow | -6.61M | 77.44M | 70.64M | 32.74M | 75.32M | 148.99M |
Fortress Biotech Technical Analysis
Neutral
3.34
Price Trends
3.05
Negative
2.78
Positive
2.99
Negative
Market Momentum
-0.11
Positive
49.15
Neutral
37.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBIO, the sentiment is Neutral. The current price of 3.34 is above the 20-day moving average (MA) of 3.09, above the 50-day MA of 3.05, and above the 200-day MA of 2.99, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 37.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FBIO.
Fortress Biotech Risk Analysis
Fortress Biotech disclosed 69 risk factors in its most recent earnings report. Fortress Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Fortress Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $91.35M | 0.91 | 163.88% | ― | 14.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $25.87M | -0.43 | -221.50% | ― | ― | 71.62% | |
44 Neutral | $137.83M | -7.84 | -61.43% | ― | -100.00% | 18.25% | |
43 Neutral | $143.91M | -3.23 | -131.18% | ― | ― | 43.63% |
* Healthcare Sector Average
FBIO
Fortress Biotech
2.98
1.02
52.04%
CVM
Cel-Sci
1.49
-6.65
-81.70%
XBIT
XBiotech
2.33
-0.91
-28.09%
EQ
Equillium
2.01
1.03
105.10%
UNCY
Unicycive Therapeutics
5.40
0.77
16.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.